Sign In
Buy THTX
$3.39
+0 (+0%)
At Close: Dec 24, 2025
Theratechnologies Announces Completion of Acquisition by Future Pak
01:21pm, Thursday, 25'th Sep 2025
MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
05:10pm, Tuesday, 16'th Sep 2025
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced
Theratechnologies Inc. (TH:CA) Special Meeting Of Shareholders Of Theratechnologies Call (Transcript)
12:29pm, Friday, 12'th Sep 2025
Theratechnologies Inc. (TSX:TH:CA ) Special Meeting of Shareholders of Theratechnologies Call Company Participants Frank Holler - Chair of the Board Philippe Dubuc - Senior VP & CFO Presentation Opera
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
11:23am, Friday, 12'th Sep 2025
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased
EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV ®
MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased
MONTREAL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) announced today that it has filed and is in the process of
Theratechnologies Reports Financial Results for the Second Quarter 2025
07:30am, Wednesday, 09'th Jul 2025
MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported
Theratechnologies to Announce Second Quarter 2025 Financial Results
05:30pm, Thursday, 03'rd Jul 2025
MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announce
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
10:11pm, Wednesday, 02'nd Jul 2025
MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announc
Theratechnologies Reports on its Annual Meeting of Shareholders
02:00pm, Thursday, 29'th May 2025
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the vo
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
12:01pm, Friday, 18'th Apr 2025
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV
Theratechnologies Provides Update on Sale Process
06:00pm, Tuesday, 15'th Apr 2025
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announ
Soleus Capital Issues Letter to The Board of Theratechnologies
08:46am, Saturday, 12'th Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Soleus Capital Management, L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX
